ADC shrinks brain metastases in HER2+ breast cancer patients
Phase II results show a high intracranial response rate in breast cancer patients with active brain metastases treated with trastzumab deruxtecan (T-Dxd), an antibody-drug conjugate (ADC).
List view / Grid view
Phase II results show a high intracranial response rate in breast cancer patients with active brain metastases treated with trastzumab deruxtecan (T-Dxd), an antibody-drug conjugate (ADC).
MR-guided focused ultrasound safely delivered antibody therapy to breast cancer that has metastasised to the brain in Phase I study.
Cancer researchers are now closer to creating a blood test that can identify breast cancer patients who are at increased risk for developing brain metastasis...